Loading...

Purified anti-human FOXP3 Antibody

Pricing & Availability
Clone
206D (See other available formats)
Regulatory Status
RUO
Other Names
Forkhead box protein P3, Scurfin, JM2, IPEX, Zinc finger protein JM2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
206D_110105
Cell extract from HEK293T cells transfected with human FoxP3 cDNA was resolved by electrophoresis, transferred to nitrocellulose, and probed with monoclonal anti-FoxP3 antibody (clone 206D). Proteins were visualized using a goat anti-mouse secondary conjugated to HRP and a chemiluminescence detection system.
  • 206D_110105
    Cell extract from HEK293T cells transfected with human FoxP3 cDNA was resolved by electrophoresis, transferred to nitrocellulose, and probed with monoclonal anti-FoxP3 antibody (clone 206D). Proteins were visualized using a goat anti-mouse secondary conjugated to HRP and a chemiluminescence detection system.
Compare all formats
Cat # Size Price Quantity Check Availability Save
320101 25 µg 104€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
320102 100 µg 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

FOXP3 is a 50-55 kD transcription factor, also known as Forkhead box protein P3, Scurfin, JM2, or IPEX. It is proposed to be a master regulatory gene and more specific marker of T regulatory cells than most cell surface markers (such as CD4 and CD25). Transduced expression of FOXP3 in CD4+/CD25- cells has been shown to induce GITR, CD103, and CTLA4 and impart a T regulatory cell phenotype. FOXP3 is mutated in X-linked autoimmunity-allergic dysregulation syndrome (XLAAD or IPEX) in humans and in "scurfy" mice. Overexpression of FOXP3 has been shown to lead to a hypoactive immune state suggesting that this transcriptional factor is a central regulator of T cell activity. In human, unlike in mouse, two isoforms of FOXP3 have been reported: one (FOXP3) corresponding to the canonical full-length sequence; the other (FOXP3 δ2) lacking exon 2. The 206D antibody recognizes human FOXP3 epitope in the region of amino acids 105-235.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Baboon, Cynomolgus, Rhesus, Pigtailed Macaque
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full-length FOXP3 protein
Formulation
This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

WB - Quality tested
ICFC, IHC-F, IHC-P - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent intracellular staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume. For Western blotting, the suggested working dilution(s) is ≤ 5.0 µg/ml in antibody dilution buffer. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1 and formalin-fixed paraffin-embedded sections1,8,19-20, and Western blotting1. The binding of 206D to FOXP3 can be partially blocked by 259D, but 206D does not show significant blocking effect on 259D binding.

NOTE: For flow cytometric staining with this clone, True-Nuclear™ Transcription Factor Buffer Set (Cat. No. 424401) offers improved staining and is highly recommended.

Application References
  1. Roncador G, et al. 2005. Eur. J. Immunol. 35:1681.(IHC)
  2. Yang ZZ, et al. 2006. Blood 107:3639.
  3. Liu W, et al. 2006. J. Exp. Med. 203:1701.PubMed
  4. Bollyky PL, et al. 2007. J. Immunol. 179:744.
  5. Bell MP, et al. 2007. J. Immunol. 179:1893.
  6. Tran DQ, et al. 2007. Blood doi:10.1182/blood-2007-06-094656. PubMed
  7. Gao Q,et al.2007.J Clin Oncol.25:2586.(IHC) PubMed
  8. Pillai V,et al. 2008. Blood 111:463. PubMed
  9. Zheng Y, et al. 2008. J. Immunol. 181:1683. PubMed
  10. Zonios DI, et al. 2008.Blood112:287. PubMed
  11. Kavanagh B, et al. 2008. Blood. PubMed
  12. Nevala WK, et al. 2009. Clin Cancer Res. 15:1931. PubMed
  13. Grant J, et al. 2009. Cytometry B Clin Cytom. 76:69. PubMed
  14. Nigam P, et al. 2010. J. Immunol. 184:1690. PubMed
  15. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (ICFC) PubMed
  16. Hartigan-O'Connor DJ,et al.2007.J Exp Med.204:2679. PubMed
  17. Raghaven S, et al. 2009. Ann Rheum Dis. 68:1908. PubMed
  18. Hodi FS, et al. 2014. Cancer Immunol Res. 2:632.(IHC) PubMed
  19. Sziros E, et al. 2015. Clin Cancer Res. 21:2840.(IHC) PubMed
Product Citations
  1. Martini R, et al. 2022. Cancer Discov. 12:2530. PubMed
  2. Gregory S, et al. 2023. Am J Cancer Res. 12:5564. PubMed
  3. Chen S, et al. 2020. Transl Lung Cancer Res. 1.404861111. PubMed
  4. Kavanagh B, et al. 2008. Blood. 112:1175. PubMed
  5. Chen P, et al. 2021. J Immunother Cancer. 9:. PubMed
  6. Haymaker C, et al. 2021. Cancer Discov. 11:1996. PubMed
  7. Richardson LG, et al. 2020. Oncoimmunology. 9:1806662. PubMed
  8. Riquelme E et al. 2019. Cell. 178(4):795-806 . PubMed
  9. Parra E,et al. 2017. Sci Rep.. 10.1038/s41598-017-13942-8. PubMed
  10. Nugent JL, et al. 2021. iScience. 24:103421. PubMed
  11. Karandikar V 2008. Blood. 111:463. PubMed
  12. Werneburg S, et al. 2020. Immunity. 52(1):167-182.e7.. PubMed
  13. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  14. Mitra A, et al. 2020. Nat Commun. 11:1839. PubMed
  15. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
  16. Burlingame EA, et al. 2021. Cell Rep Methods. 1:. PubMed
  17. Boucher Y, et al. 2021. NPJ Precis Oncol. 5:62. PubMed
  18. Derks S, et al. 2020. Ann Oncol. 31:1011. PubMed
  19. Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed
  20. Vence L, et al. 2019. Clin Cancer Res. 25:6501. PubMed
  21. de Groot J, et al. 2020. Neuro Oncol. 539:22. PubMed
  22. Helmink BA, et al. 2020. Nature. 577:549. PubMed
  23. Li W, et al. 2018. BMC Cancer. 1.589583333. PubMed
  24. Xie S, et al. 2020. Ann Transl Med. 1.384027778. PubMed
  25. Zeigler-Johnson C, et al. 2016. PLoS One. 11: 0159109. PubMed
  26. Gao Q, et al. 2007. J Clinical Oncololgy. 25:2586. PubMed
  27. Donnelly C, et al. 2018. Sci Rep. 0.625. PubMed
  28. Msaouel P, et al. 2020. Cancer Cell. 720:37. PubMed
  29. Wang H, et al. 2021. Onco Targets Ther. 14:2953. PubMed
  30. Hodi F, et al. 2014. Cancer Immunol Res. 2:632. PubMed
  31. Zsiros E, et al. 2015. Clin Cancer Res. 21:2840. PubMed
  32. Sadigh S, et al. 2020. Am J Clin Pathol. 387:153. PubMed
  33. Durgin JS, et al. 2021. Front Oncol. 11:669071. PubMed
  34. Jiang M, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  36. Amaria RN, et al. 2018. Nat Med. 24:1649. PubMed
  37. Blessin NC, et al. 2019. Dis Markers. 2019:5160565. PubMed
  38. Zonios D, et al. 2008. Blood. 112:287. PubMed
RRID
AB_430880 (BioLegend Cat. No. 320101)
AB_430880 (BioLegend Cat. No. 320102)

Antigen Details

Structure
Forkhead/winged-helix transcription factor family, approximately 50 kD, contains zinc finger and forkhead domains
Distribution

Nuclear; expressed in T regulatory cells

Function
Transcription factor proposed to be a master regulatory gene in T regulatory cell development and a critical factor for immune homeostasis
Interaction
Interacts with DNA
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Transcription Factors
Molecular Family
Nuclear Markers
Antigen References

1. Hori S, et al. 2003. Science 299:1057.
2. Gandhi R, et al. 2010. Nat. Immunol. 11:846.

Regulation
FOXP3 is present at high levels in T regulatory cells, it can also be induced by T cell activation.
Gene ID
50943 View all products for this Gene ID
UniProt
View information about FOXP3 on UniProt.org

Related FAQs

Can I stain whole blood with anti-FOXP3 using your Foxp3 staining kit?

It is not recommended. It is best to use PBMCs for this testing.

Can FOXP3 be costained with cytokines?

The larger holes created by the nuclear permeabilization required for FOXP3 may allow cytokines to leak out of the cell, making it harder to detect lowly-expressed cytokines. You may have to use a control where the cells are only permeabilized through the cell membrane.

Go To Top Version: 5    Revision Date: 08/16/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account